David Meeker, MD
Executive Vice President, Therapeutics, Biosurgery and Transplant
Genzyme

David Meeker joined Genzyme in 1994 as Medical Director to work on the Cystic Fibrosis Gene Therapy program.

Subsequently, as Vice President, Medical Affairs, David was responsible for the development of therapeutic products, including products in the current LSD portfolio, prior to his promotion to Senior Vice President in 1998. In 2000, he assumed the position of Business Unit Leader for Genzyme’s Lysosomal Storage Disease and Thyrogen® programs in Europe. In March 2003, he was promoted to President of the Global LSD Business unit. David has overseen the global launches of Aldurazyme®, Fabrazyme®, and Myozyme®. In May 2008, David was promoted to Executive Vice President and now oversees the Biosurgery and Transplant Business Units, as well as Therapeutics.

Prior to joining Genzyme, David was the Director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic. He has authored more than 40 articles and multiple book chapters. David is currently a Board member of Penwest Pharmaceuticals Inc, and a member of the Scientific Advisory Board of Prize4Life, an organization dedicated exclusively to promoting research and development objectives in Amyotrophic Lateral Sclerosis.

David attended Dartmouth College and received his medical doctorate from the University of Vermont Medical School. He completed an Internal Medicine residency at Beth Israel Hospital in Boston and a Pulmonary/Critical Care fellowship at Boston University. David completed the Advanced Management Program at Harvard Business School in 2000.